Educational Panel : Neuroscience of Addiction: Levers to Attack the Opioid Abuse Crisis

feb 13, 2018: 9 a.m. - 9:55 a.m.
Salon 4

With official recognition of the magnitude of the opioid abuse crisis, government institutions and investors are showing increased willingness to support novel approaches to attacking this health challenge.  This session will explore the most promising avenues in the neuroscience of addiction and alternatives to opioid-based pain management, as well as identify the most pressing bottlenecks in our understanding of the brain’s addiction to painkillers.

Data Introduction: David Thomas, CFA, Senior Director, Industry Research & Analysis, Biotechnology Innovation Organization

Moderator: Michael Detke, MD, PhD, Chief Medical Officer, Embera NeuroTherapeutics, Inc.


Roger Crystal, MD, Chief Executive Officer, Opiant

Brandon Folkes, Director, Specialty Pharmaceuticals Analyst, Cantor Fitzgerald

Lucy Lu, MD, President and CEO, Avenue Therapeutics

Corey McCann, MD, PhD, Founder and Chief Executive Officer, Pear Therapeutics

Robert Radie, President and Chief Executive Officer, Egalet Corporation

Peter Strumph, President and Chief Executive Officer, Amygdala Neurosciences Inc.


Brandon Folkes
Director, Specialty Ph...

Roger Crystal, MD
Chief Executive Officer

Lucy Lu, MD
President and CEO

Corey McCann, MD, PhD
Founder and Chief Exec...

Michael Detke, MD, PhD
Chief Medical Officer

Peter Strumph
President and Chief Ex...